Mustang Bio, Inc. (NASDAQ:MBIO – Get Free Report) was the target of a significant decline in short interest in March. As of March 15th, there was short interest totalling 44,000 shares, a decline of 52.0% from the February 28th total of 91,700 shares. Approximately 2.8% of the company’s stock are sold short. Based on an average daily trading volume, of 316,300 shares, the days-to-cover ratio is currently 0.1 days.
Institutional Investors Weigh In On Mustang Bio
A hedge fund recently raised its stake in Mustang Bio stock. Geode Capital Management LLC grew its holdings in shares of Mustang Bio, Inc. (NASDAQ:MBIO – Free Report) by 15.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 284,437 shares of the company’s stock after buying an additional 38,951 shares during the period. Geode Capital Management LLC owned 29.63% of Mustang Bio worth $50,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 9.95% of the company’s stock.
Mustang Bio Price Performance
Shares of MBIO stock traded down $0.09 during trading hours on Friday, reaching $1.33. 73,124 shares of the stock were exchanged, compared to its average volume of 244,964. The business’s fifty day moving average is $2.65 and its two-hundred day moving average is $8.03. The firm has a market capitalization of $1.27 million, a P/E ratio of -0.02 and a beta of 1.82. Mustang Bio has a 12-month low of $1.26 and a 12-month high of $65.00.
Mustang Bio Company Profile
Mustang Bio, Inc, a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
Featured Stories
- Five stocks we like better than Mustang Bio
- 3 REITs to Buy and Hold for the Long Term
- Venezuelan Tariffs Could Power These 3 Diesel-Driven Winners
- Roth IRA Calculator: Calculate Your Potential Returns
- MarketBeat Week in Review – 03/24 – 03/28
- Earnings Per Share Calculator: How to Calculate EPS
- Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low
Receive News & Ratings for Mustang Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mustang Bio and related companies with MarketBeat.com's FREE daily email newsletter.
